NEUROPSYCHOLOGICAL OUTCOME OF ZIDOVUDINE (AZT) TREATMENT OF PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX
NEUROPSYCHOLOGICAL OUTCOME OF ZIDOVUDINE (AZT) TREATMENT OF PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX
复制标题
DOI：
10.1056/nejm198812153192404
复制
发表时间：
1988-12-15
影响因子：
158.5
通讯作者：
DRUCKER, JL
中科院分区：
文献类型：
--
作者：
SCHMITT, FA;BIGLEY, JW;DRUCKER, JL
281 名患有获得性免疫缺陷综合症 (AIDS) 或晚期艾滋病相关综合症的患者参加了一项双盲、安慰剂对照试验，研究口服齐多夫定（叠氮胸苷或 AZT）的有效性和安全性。该试验报告了显着的临床益处和不良经历。由于神经精神功能障碍通常与人类免疫缺陷病毒 (HIV) 感染有关，因此在试验的 16 周内进行了简短的情感和神经心理学检查，以评估给药过程中发生的神经心理功能的任何变化。与接受安慰剂的患者相比，接受齐多夫定的患者，尤其是艾滋病患者，认知能力有所改善。情感症状没有变化。在试验期间，齐多夫定接受者的症状困扰强度也有统计学上的显着降低，这可能部分解释了观察到的认知变化。患有艾滋病相关综合症的患者的各种认知指标也有所改善。这项研究的结果表明，服用齐多夫定后，与艾滋病毒相关的认知异常可能会得到部分改善。
Two hundred eighty-one patients with the acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex were enrolled in a double-blind, placebo-controlled trial of the efficacy and safety of orally administered zidovudine (azidothymidine or AZT). Significant clinical benefits and adverse experiences have been reported from this trial. Because neuropsychiatric dysfunction is often associated with human immunodeficiency virus (HIV) infection, a brief affective and neuropsychological examination was administered over 16 weeks of the trial to evaluate any changes in neuropsychological function that occurred with drug administration. Patients receiving zidovudine, particularly those with AIDS, showed improved cognition as compared with patients receiving placebo. There were no changes in affective symptoms. The zidovudine recipients also had a statistically significant reduction in the intensity of symptomatic distress during the trial that may account in part for the observed cognitive changes. Some improvement in various cognitive measures was also seen in patients with AIDS-related complex. The results of this study suggest HIV-associated cognitive abnormalities may be partially ameliorated after the administration of zidovudine.